Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03906071 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by Mirati Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 577
- Enrollment target
NCT03906071: Completed Phase 3 study, sponsored by Mirati Therapeutics.
NCT03906071 is a Phase 3 study that has completed, run by Mirati Therapeutics. The registered enrollment target is 577 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03906071, a Phase 3 study, has completed, sponsored by Mirati Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 577 participants
- Enrollment target
Study Summary
This study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression on or after platinum-based chemotherapy and checkpoint inhibitor therapy.
Primary Outcome
OS is defined as time from date of randomization to date of death due to any cause. Patients who did not die on study are censored at the date of the last on-study follow-up that the patient was known to be alive (including follow-up data). Results obtained via Kaplan-Meier estimation, Brookmeyer and Crowley (1982) method.
Interventions
- DRUG Docetaxel
- BIOLOGICAL Nivolumab
- DRUG Sitravatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 577 participants |
| Start Date | 2019-07-15 |
| Est. Completion | 2025-09-30 |
| Phase | Phase 3 |
What the finished NCT03906071 record still lists
NCT03906071 is an interventional study that assigns participants to a tested intervention. The registered 577 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (25% lower).
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT03906071 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03906071 about?
NCT03906071 is a clinical study titled "Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer". This study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression on or after platinum-based chemotherapy and checkpoint inhibitor therapy.
What is the current status of trial NCT03906071?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 577 participants. The study started on 2019-07-15. Estimated completion is 2025-09-30.
What interventions are being tested in trial NCT03906071?
The interventions under investigation include: Docetaxel (DRUG), Nivolumab (BIOLOGICAL), Sitravatinib (DRUG).
Who is sponsoring clinical trial NCT03906071?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03906071's enrollment target sits among peer trials
577 661st of 2000 higher than 1,340 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07290543 · 578 participants · NA
Web-Based Toolkit to Improve Cancer-Related Emotional Distress and Anxiety in Rural Older Cancer Survivors
- NCT04931810 · 576 participants · NA
Urban and Reservation Implementation of All Nations Breath of Life
- NCT05179369 · 576 participants · NA
Well-Mama Community Doula Navigator Study
- NCT06398509 · 576 participants · NA
A Primary Care Based Intervention to Prevent Childhood Obesity Among Low-income Latino Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI